

List of References Cited by Applicant

Atty Docket No.:	13783-105023		
Applicant (s):	Koenig et al.	Serial No.:	10/524,134
Filing Date:	February 11, 2005	Group Art Unit:	1644

U.S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass	Filing Date if appropriate
	A18	6,737,056	5/18/2004	Presta			
	A19	2004/0002587	1/1/2004	Watkins et al.			
	A20	2004/0185045 A1	9/23/2004	Koenig et al.			
	A21	2005/0037000 A1	2/17/2005	Stavenhagen et al.			
	A22	2005/0215767	9/29/2005	Koenig et al.			
	A23	2005/0260213 A1	11/24/2005	Koenig et al.			
	A24	2006/0013810	1/19/2006	Johnson et al.			
	A25	2006/0073142	4/6/2006	Chan et al.			
	A26	2006/0177439	8/10/2006	Koenig et al.			
	A27	2007/0253948	11/1/2007	Chan et al.			
	A28	11/754,015		Johnson et al.			5/25/2007
	A29	11/768,852		Johnson et al.			6/26/2007

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Class	Subclass	Translation Yes/No
	B15	WO 04/016750 A2	2/26/2004	PCT			
	B16	WO 05/110474 A2	11/24/2005	PCT			
	B17	WO 05/115452 A2	12/08/2005	PCT			
	B18	WO 06/066078 A2	6/22/2006	PCT			
	B19	PCT/US07/72151		PCT; filing date: June 26, 2007			

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	C83	Boruchov et al., Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. The Journal of Clinical Investigation 115; 10:2914-2923.
	C84	Ott et al. FcγRIIB as a potential molecular target for intravenous gamma globulin therapy. J Allergy Clin Immunol. 2001; 108:S95-S98.

	C85	Pardridge et al., Blood-brain barrier drug targeting: The future of brain drug development. Molecular Interventions. 2003, 3;2:90-105. See particularly pages 91-96.
	C86	Reff et al. A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications. Crit Rev Oncol Hematol. 2001; 40(1):25-35
	C87	Su et al., Expression profile of FcγRIIB on leukocytes and its dysregulation in systemic lupus erythematosus. J. Immunol. 178:3272-3280, 2007

EXAMINER /Chun Crowder/ (02/12/2008)	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	